These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1256 related items for PubMed ID: 26563121

  • 1. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, Mottaghy FM, Behrendt FF.
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [Abstract] [Full Text] [Related]

  • 2. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.
    Radiat Oncol; 2017 Nov 10; 12(1):176. PubMed ID: 29126446
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study.
    Lengana T, van de Wiele C, Lawal I, Maes A, Ebenhan T, Boshomane T, Zeevaart JR, Ankrah A, Mokgoro N, Vorster M, Sathekge M.
    Nucl Med Commun; 2018 Feb 10; 39(2):179-185. PubMed ID: 29257006
    [Abstract] [Full Text] [Related]

  • 4. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
    Verburg FA, Pfister D, Drude NI, Mottaghy FM, Behrendt FF.
    Nuklearmedizin; 2017 Feb 10; 56(6):225-232. PubMed ID: 29044297
    [Abstract] [Full Text] [Related]

  • 5. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
    Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M.
    Clin Nucl Med; 2016 Sep 10; 41(9):e397-402. PubMed ID: 27276206
    [Abstract] [Full Text] [Related]

  • 6. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 7. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 15; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 8. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, Darendeliler E, Ozluk Y, Yildiz SO, Turkmen C.
    Ann Nucl Med; 2017 Nov 15; 31(9):709-717. PubMed ID: 28900854
    [Abstract] [Full Text] [Related]

  • 9. 68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer.
    Akdemir EN, Tuncel M, Akyol F, Bilen CY, Baydar DE, Karabulut E, Ozen H, Caglar M.
    World J Urol; 2019 May 15; 37(5):813-821. PubMed ID: 30151600
    [Abstract] [Full Text] [Related]

  • 10. Integrated 68Ga-HBED-CC-PSMA-PET/MRI in patients with suspected recurrent prostate cancer.
    Lütje S, Cohnen J, Gomez B, Grüneisen J, Sawicki L, Rübben H, Bockisch A, Umutlu L, Pöppel TD, Wetter A.
    Nuklearmedizin; 2017 Jun 13; 56(3):73-81. PubMed ID: 28401244
    [Abstract] [Full Text] [Related]

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jun 13; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 12. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
    Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2015 Jul 13; 42(8):1284-94. PubMed ID: 25975367
    [Abstract] [Full Text] [Related]

  • 13. Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI.
    Jannusch K, Bruckmann NM, Morawitz J, Boschheidgen M, Quick HH, Herrmann K, Fendler WP, Umutlu L, Stuschke M, Hadaschik B, Antoch G, Schimmöller L, Kirchner J.
    Eur Radiol; 2024 Jul 13; 34(7):4789-4800. PubMed ID: 38038758
    [Abstract] [Full Text] [Related]

  • 14. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.
    Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U, Klutmann S, Beyersdorff D, Budäus L, Wester HJ, Mester J, Bannas P.
    Eur J Nucl Med Mol Imaging; 2017 Apr 13; 44(4):670-677. PubMed ID: 27896369
    [Abstract] [Full Text] [Related]

  • 15. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.
    J Nucl Med; 2015 Aug 13; 56(8):1185-90. PubMed ID: 26112024
    [Abstract] [Full Text] [Related]

  • 16. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W.
    Mol Imaging Biol; 2016 Jun 13; 18(3):428-36. PubMed ID: 27038316
    [Abstract] [Full Text] [Related]

  • 17. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M.
    J Nucl Med; 2016 Nov 13; 57(11):1713-1719. PubMed ID: 27261524
    [Abstract] [Full Text] [Related]

  • 18. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.
    De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M, Cavalleri S, Salgarello M, Alongi F.
    Radiol Med; 2018 Sep 13; 123(9):719-725. PubMed ID: 29687208
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
    Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, Wetterauer U, Schultze-Seemann W, Meyer PT.
    Theranostics; 2017 Sep 13; 7(6):1770-1780. PubMed ID: 28529650
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.
    Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2017 Aug 13; 44(8):1258-1268. PubMed ID: 28497198
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.